Pioglitazone

Stroke

Milton S. Hershey Medical CenterSmall moleculePhase 3Dormant

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 65/ 100

Competitive context

133 Active assets in the Stroke cohort.

Asset / Sponsor	Phase	Rating
Aggrenox Boehringer Ingelheim	Phase 4	BBB
INCOBOTULINUMTOXINA Parc de Salut Mar	Phase 4	BBB
ATENOLOL Northern California Institute of Research and Education	Phase 4	BBB
Dextromethorphan University of Florida	Phase 4	BBB
Tenecteplase Assistance Publique - Hôpitaux de Paris	Phase 4	BBB

View all 50 →

Same molecule, other indications

Pioglitazone is also rated in:

diabetes mellitusDormant

BBB

Indicative ·

79 / 100

metabolic dysfunction-associated steatohepatitisDormant

BBB

Indicative ·

75 / 100

abdominal obesity-metabolic syndromeDormant

BBB

Indicative ·

73 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.